Clinical trials: Helicobacter Pylori Resistance, active
Helicobacter Pylori Gastritis, Helicobacter Eradication
Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia
The goal of this clinical trial is to learn if a modified bismuth-containing therapy for the treatment of helicobacter pylori infection works to treat chronic helicobacter pylori related gastritis in adults treated either for…
- Trial name
- MBISQ4HP (NCT07146594)
- Testing
- Modified bismuth-containing eradication treatment
- Volunteers
- 150 people
- Sponsor
- Athens Medical Center
Helicobacter Pylori Infection
Tailored Vs. Empirical Helicobacter Pylori Infection Treatment
Helicobacter pylori (Hp) is a gram-negative bacterium that colonizes human gastric mucosa and is associated with chronic gastritis that can progress to severe complications such as peptic ulcer disease, gastric adenocarcinoma and…
- Trial name
- NCT06200779
- Testing
- Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test, Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®), PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
- Where
- Portugal
- Volunteers
- 160 people
- Sponsor
- Manuel Coelho da Rocha
Helicobacter Infections
A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children
With the resistance of Helicobacter pylori increasing, low and unsatisfactory eradication rate (64%) have been observed with standard triple therapy in European children.
- Trial name
- NCT03365609
- Testing
- triple therapy, sequential therapy, bismuth quadruple therapy
- Where
- China
- Volunteers
- 1,440 people
- Sponsor
- Ying HUANG
Metabolic Syndrome
Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metabolic Syndrome
This retrospective cohort study evaluates the association between H. pylori persistence and insulin resistance severity (HOMA-IR) in 100 patients with metabolic syndrome at Novosibirsk's Center for New Medical Technologies…
- Trial name
- NCT07501858
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Center of New Medical Technologies
Helicobacter Pylori Infection, Helicobacter Pylori Associated Gastrointestinal Disease
Prevalence and Trends of Antimicrobial Resistance of Helicobacter Pylori in Korea
To assess antimicrobial resistance rates and minimal inhibitory concentrations in H. pylori isolated from patients with upper gastrointestinal disease with long-term period.
- Conditions
- Helicobacter Pylori Infection, Helicobacter Pylori Associated Gastrointestinal Disease, Helicobacter Pylori Infection, Susceptibility to, Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation
- Trial name
- NCT05247112
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Pylori Infection, Helicobacter Pylori Gastritis
Helicobacter Pylori Local Prevalence and Antibiotic Resistance
The clinical management of H. pylori infection depends essentially on two factors, prevalence and local resistance. In Germany, only limited data from rather small cohorts currently exist regarding both factors.
- Conditions
- Helicobacter Pylori Infection, Helicobacter Pylori Gastritis, Drug Resistant Bacterial Infection, Antibiotic Resistant Infection
- Trial name
- HelicoPTER (NCT05561504)
- Where
- Germany
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Helicobacter Pylori Infection
Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication
To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without…
- Trial name
- NCT07439445
- Testing
- Vonoprazan 20 mg twice daily + clarithromycin 500 mg twice daily for 14 days
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University First Hospital
HELICOBACTER PYLORI INFECTIONS
Feasibility and Performance of FFPE qPCR for Detection of Clarithromycin Resistance in Helicobacter Pylori
This prospective observational study aims to evaluate the feasibility and performance of real-time PCR (qPCR) performed on formalin-fixed, paraffin-embedded (FFPE) gastric biopsies to detect Helicobacter pylori infection and…
- Trial name
- HED-2T (NCT07821294)
- Testing
- q-PCR on FFPE gastric biopsies
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Clinique Bizet
HELICOBACTER PYLORI INFECTIONS, Metabolic Syndrome
Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.
The Role of Gut Microbiota in the Mechanism of Helicobacter pylori Eradication-Induced Amelioration of Metabolic Syndrome-Related Parameters Study Sponsor: Nanjing First Hospital Principal Investigator: Dr.
- Trial name
- NCT07306988
- Testing
- Vonoprazan-Amoxicillin Dual Therapy, Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae, Vonoprazan-Amoxicillin with Berberine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
HELICOBACTER PYLORI INFECTIONS, Rescue Therapy for Helicobacter Pylori
Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing
Helicobacter pylori(H. pylori, Hp) is a major etiological agent in chronic gastritis, peptic ulcer disease, gastric cancer, and gastric MALT lymphoma.
- Trial name
- NCT07533422
- Testing
- Personalized treatment based on the results of fecal antimicrobial resistance gene testing, Conventional Quadruple Therapy
- Volunteers
- 531 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Helicobacter Pylori Infection
Tegoprazan-containing Sequential for H. Pylori
As H. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional PPI-containing 10-day sequential…
- Trial name
- NCT06382493
- Testing
- Tegoprazan-containing sequential H. pylori eradication therapy, Esomeprazole-containing sequential H. pylori eradication therapy
- Where
- South Korea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital